Michael W.N. Deininger, MD, PhD
Dr. Michael W.N. Deininger is Professor and Chief of Hematology and Hematologic Malignancies in the Department of Internal Medicine and the Huntsman Cancer Institute (HCI) at the University of Utah. He is an HCI investigator and member of the experimental therapeutics program.
Dr. Deininger’s scientific focus is leukemia, specifically myeloproliferative neoplasms including chronic myeloid leukemia (CML), chronic myelomonocytic leukemia, and myelofibrosis. As a clinician-scientist with a translational research focus, Dr. Deininger is heading an extramurally funded research laboratory that is dedicated to the study of signaling pathways, drug resistance, and new molecular therapies in leukemia. Dr. Deininger’s work describing the selective effects of imatinib on CML cells provided the rationale for clinical trials that led to the approval of imatinib (Gleevec) as the first molecularly based therapy for leukemia. Dr. Deininger has written more than 200 articles that are published in Cancer Cell, Blood, the Journal of Clinical Investigation, and The New England Journal of Medicine. He has co-written more than 10 book chapters that have appeared in leading textbooks such as deVita’s Principles of Oncology. He is a peer reviewer for Nature Genetics and Cancer Cell. Dr. Deininger serves as the Vice-Chair for the National Comprehensive Cancer Network® (NCCN) CML guidelines panel and is a member of the NCCN myeloproliferative neoplasm guidelines panel.
Dr. Deininger earned an MD degree from the University of Würzburg Medical School, Germany, where he completed additional training in internal medicine and hematology/oncology. He earned a PhD degree from Imperial College in London.
Ehab Atallah, MD
Dr. Ehab Atallah is Associate Professor of Medicine in the Division of Hematology and Oncology at the Medical College of Wisconsin, specializing in leukemia and myelodysplastic syndromes at Froedtert Hospital.
Dr. Atallah is board certified in internal medicine, medical oncology, and hematology. He has written numerous publications, including journal articles, meeting abstracts, and a book chapter. His current research interests are the treatment of leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms with special emphasis on chronic myeloid leukemia.
Dr. Atallah earned an MD degree from Cairo University School of Medicine and completed an internal medicine residency at the Cleveland Clinic Health System and a fellowship in hematology/oncology at the Karmanos Cancer Center in Detroit, Michigan, where he also served as chief fellow. He also completed a leukemia fellowship at MD Anderson Cancer Center in Houston, Texas.
Dale L. Bixby, MD, PhD
Dr. Dale L. Bixby is a Clinical Associate Professor of hematology and the Inpatient Hematology Director in the Division of Hematology/Oncology, Department of Internal Medicine at the University of Michigan in Ann Arbor. He is also the Interim Medical Director of the University of Michigan Adult Bone Marrow Transplant and Leukemia acute care unit.
Dr. Bixby’s clinical interests include the care and management of patients with acute and chronic leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, and bone marrow failure disorders. His research interests are in the clinical trial development of novel therapeutics for patients with advanced myeloid neoplasms. Dr. Bixby has written articles that were published in Clinical Lymphoma and Myeloma, International Journal of Cancer, and Cell Cycle. He is a member of the American Society of Clinical Oncology and American Society of Hematology and is board certified in internal medicine, medical oncology, and hematology.
Dr. Bixby earned a PhD from the University of Kentucky College of Pharmacy in Lexington. He earned an MD from the University of Michigan Medical School and completed a residency and fellowship (hematology/oncology) at the University of Michigan Health System in Ann Arbor.
Jorge E. Cortes, MD
Dr. Jorge E. Cortes is Deputy Chair and Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, where he directs the chronic myeloid leukemia and acute myeloid leukemia programs. Dr. Cortes is Chair of the executive institutional review board and Chair of the executive committee of the medical staff at MD Anderson Cancer Center and program director of the Leukemia Fellowship Program.
Dr. Cortes, whose clinical interest focuses on new drug development and the management of myelodysplastic syndromes, acute and chronic leukemias, and myeloproliferative disorders. He led the development of 3 drugs that were were approved by the FDA for the treatment of chronic myeloid leukemia. He has written more than 700 peer-reviewed medical publications that have appeared in The New England Journal of Medicine, Lancet Oncology, and Lancet Hematology, among others. He has written several book chapters in prestigious publications such as Cancer Medicine and Harrison’s Principles of Internal Medicine. He has received numerous awards including the William Randolph Hearst Foundations Faculty Achievement Award in Education and The Gerald P. Bodey Award for Excellence in Education..
Dr. Cortes is an Associate Editor for Blood and serves on the editorial board of the Journal of Clinical Oncology, Clinical Cancer Research, Leukemia and Lymphoma, and the American Journal of Hematology. He is a member of the board of directors of the International CML Foundation and President of the Latin American LeukemiaNet.
Dr. Cortes earned an MD degree from the Universidad Nacional Autonoma de Mexico, Mexico City. He completed a residency in internal medicine and a fellowship in hematology at the Instituto Nacional de la Nutricion Salvador Zubiran, Mexico City, Mexico; and a hematology fellowship at the University of Texas Health Science Center in Houston.
H. Jean Khoury, MD, FACP
Dr. H. Jean Khoury is a Professor of Hematology and Medical Oncology, recipient of the R. Randall Rollins Chair in Oncology, and Director of the Division of Hematology, in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Khoury attended the Jesuit Facultés Universitaires Notre-Dame de la Paix, Namur, Belgium for his undergraduate degree, and the Université Catholique de Louvain, Brussels, Belgium where he received his medical degree. He completed his residency in Internal Medicine at Memorial Medical Center, in Savannah, Georgia, his fellowship in Hematology-Oncology and a bone marrow transplantation fellowship at Washington University School of Medicine in St. Louis, Missouri. Dr. Khoury is a fellow of the American Association of Cancer Research/ American Society of Clinical Oncology Methods in Clinical Cancer Research Workshop, and the Robert W. Woodruff Health Sciences Center Woodruff Leadership Academy.
Dr. Khoury’s clinical and research interests focus of drug development in bone marrow transplantation, leukemia and myelodysplasia, new approaches for the prevention and treatment of acute graft versus-host-disease, and the identification of genetic markers that predict outcomes in patients with hematological cancers. He established the leukemia tissue bank at Washington University and the Hematology tissue bank at Emory University. He published as first, senior or co-author more than 130 peer-reviewed manuscripts in high-impact journals such as the New England Journal of Medicine, Cancer Cell, Nature Communications, Journal of Clinical Oncology, and Blood. Dr. Khoury conducted more than 50 phase 1, 2 and 3 clinical trials.
Dr. Khoury has mentored 20 medical students, residents and fellows who now hold academic positions in top academic centers. He was awarded the Distinguished Service Teaching Award by the 2004 Medical Students at Washington University School of Medicine and was elected to the Alpha Omega Alpha National Honor Medical Society by the 2009 Medical Students at Emory University. He teaches at the Emory University School of Medicine, Emory University School of Physician Assistant and the Emory Nell Hodgson Woodruff School of Nursing. As a Master with a Kukkiwon certified 4th degree black belt, Dr. Khoury also teaches the Korean martial art of Taekwondo.
Dr Khoury serves on the Emory Hematology Oncology Academic Development Advisory Committee and the Coalition on Patient Satisfaction. At the national level, he serves as the Hematological Malignancies Section Editor for the Journal Cancer, the Government Affair Committee of the American Society of Hematology, and the Cancer Education Committee for the American Society of Clinical Oncology. He is the Co-Chair of the Acute Leukemia Working Committee for the Center for International Blood and Marrow Transplant Research, and the American Society of Hematology representative for the Post-Masters Foundation in Hematology Course for the Advanced Practice Provider Planning Committee.
Richard A. Larson, MD
Dr. Richard A. Larson is a Professor of Medicine in the Section of Hematology/Oncology and Director of the Hematologic Malignancies Clinical Research Program at the University of Chicago. He is board certified in internal medicine, hematology, and medical oncology.
Dr. Larson’s current research interests include clinical trials in acute and chronic leukemias and stem-cell transplantation, experimental therapeutics, the determinants of response to therapy in leukemia and myelodysplastic syndromes, and the etiology of therapy-related leukemias.
Dr. Larson represents the American Society of Hematology as a member of the National Cancer Policy Forum of the Institute of Medicine. He is a member of the American Society of Clinical Oncology and the American Association for Cancer Research. He is a member of the European LeukemiaNet working groups on chronic myeloid leukemia and acute myeloid leukemia. Dr. Larson has written more than 400 papers, reviews, and book chapters on clinical and laboratory studies in human leukemias and, in addition, has served on the editorial boards of Blood, the Journal of Clinical Oncology, and Leukemia. He is a Leukemia section editor and one of three editors-in-chief for hematology for UpToDate.
Dr. Larson earned an MD degree from the Stanford University School of Medicine and completed his postdoctoral training in internal medicine, hematology, and oncology at the University of Chicago.
Vivian G. Oehler, MD
Dr. Vivian G. Oeher is an Associate Member at Fred Hutch and Associate Professor in the Division of Hematology at University of Washington. Dr. Oehler sees patients with chronic myeloid leukemia (CML) and myeloproliferative neoplasms at Seattle Cancer Care Alliance, the outpatient clinic for these institutions. Her translational research has used high-throughput gene and microRNA (miRNA) expression data sets to identify genes, miRNAs, and pathways that contribute to leukemia and therapy response in CML and acute myeloid leukemia. This work has investigated how specific candidates contribute to disease, can be targeted by existing or new therapeutic strategies and can be used to predict outcomes. She has participated in clinical trials examining various agents in the treatment of CML in addition to an investigator-initated study examining tyrosine kinase inhibitor cessation.
Dr. Oehler completed her undergraduate work at Harvard University and earned a medical degree from Case Western University School of Medicine.
Jerald P. Radich, MD
Dr. Jerald P. Radich is the Director of the Molecular Oncology Lab at the Fred Hutchinson Cancer Research Center and Professor of Medicine at the University of Washington School of Medicine in Seattle.
Dr. Radich’s laboratory work centers on the molecular biology of response, resistance, and progression in adult and chronic leukemia. He is Chair of the Leukemia Translational Medicine Committee of the Southwest Oncology Group, Co-Chair of the National Cancer Institute/National Institutes of Health (NIH) leukemia steering committee, and is on the board of scientific counselors for the NIH Genome Research Institute. He is a member of the National Comprehensive Cancer Network and the EuroLeukemiaNet (ELN) CML guidelines panels and is on the scientific board of the International CML Foundation.
Dr. Radich earned an MD degree from the University of California School of Medicine – Davis and completed a residency in internal medicine at the University of Washington Affiliated Hospitals and a fellowship in medical oncology at the University of Washington and the Fred Hutchinson Cancer Research Center.
Michael R. Savona, MD, FACP
Michael R. Savona, MD, FACP, is the Director of Hematology Research and the Director of the Hematology Early Therapeutics Program at Vanderbilt University Medical Center, and Associate Professor of Medicine at Vanderbilt University School of Medicine.
Dr. Savona is interested in developing novel therapeutics for patients with myeloid disease. The Early Therapeutics Program is focused on providing mechanistically sound therapies to appropriate patients with myeloid malignancies as quickly as possible. To this end, Dr. Savona leads an extramurally funded laboratory that focuses on preclinical development and correlative science surrounding phase 1 clinical trials in tailored in vitro and in vivo models. He is an international leader in myeloid biology and in the care of patients with hematologic malignancies and has published manuscripts in JAMA, Nature Medicine, Nature Reviews Cancer, Haematologica, and Blood. Dr. Savona is board certified in medical oncology, hematology, and internal medicine, and is an elected fellow of the American College of Physicians.
Dr. Savona earned an MD from Wake Forest University School of Medicine in Winston-Salem, North Carolina. He completed a residency at the University of California-Davis and a fellowship in hematology and oncology at the University of Michigan in Ann Arbor.